This was true for all HCV genotypes, particularly Genotype 1, in which the relapse rate was reduced by 30% compared with interferon alfa-2b monotherapy.
See oli jälgitav kõikide HCV genotüüpide, eriti genotüüp 1 puhul, kus retsidiivide arv vähenes 30% võrreldes interferoon alfa- 2b monoraviga.